Findings

What do systematic reviews say?

12 questions · 13 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 7.7%GRADE not reported 0 · 0%Very low 2 · 15.4%Low 7 · 53.8%Moderate 2 · 15.4%High 1 · 7.7%

Summary of findings: repaglinide vs placebo

Hypoglycemia: number of episodes · adults with CFRD

It is very uncertain whether summary of findings: repaglinide changes hypoglycemia: number of episodes compared with placebo (very low certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
RR 12.52 [0.74, 211.2]
1 study · 51 participants
Very low

Summary of findings: repaglinide vs insulin

HbA1c (glycated haemoglobin), change · children over 12 and adults with CFRD

Summary of findings: repaglinide showed no clear difference in hbA1c (%) change from baseline compared with insulin (high certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
MD 0.3
1 study · 67 participants
High

Summary of findings: repaglinide vs insulin

FEV1 (% predicted): mean change from baseline · children over 12 and adults with CFRD

Summary of findings: repaglinide showed no clear difference in FEV1 % predicted change from baseline compared with insulin (moderate certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 112 participants
Moderate

Summary of findings: repaglinide vs insulin

FVC (% predicted) Change from baseline · children over 12 and adults with CFRD

Summary of findings: repaglinide showed no clear difference in FVC % predicted change from baseline compared with insulin (moderate certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 112 participants
Moderate

Summary of findings: repaglinide vs insulin

Change in BMI · children over 12 and adults with CFRD

Summary of findings: repaglinide showed no clear difference in BMI (kg/m²) change from baseline compared with insulin (low certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
MD 0.24
1 study · 45 participants
Low

Summary of findings: repaglinide vs insulin

Hypoglycemia: number of episodes · children over 12 and adults with CFRD

Summary of findings: repaglinide showed no clear difference in hypoglycemia number of episodes compared with insulin (low certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
RR 1.38 [0.48, 4.01]
2 studies · 56 participants
Low

Summary of findings: repaglinide vs placebo

HbA1c (%) · adults with CFRD

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Very low

Summary of findings: repaglinide vs placebo

FEV1 (% predicted): mean change from baseline · adults with CFRD

Summary of findings: repaglinide showed no clear difference in FEV1 % predicted; change from baseline compared with placebo (low certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
MD 1.7
1 study · 38 participants
Low

Summary of findings: repaglinide vs placebo

FVC (% predicted) Change from baseline · adults with CFRD

Summary of findings: repaglinide showed no clear difference in FVC % predicted: change from baseline compared with placebo (low certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Low

Summary of findings: repaglinide vs placebo

Change in BMI · adults with CFRD

Summary of findings: repaglinide showed no clear difference in BMI (kg/m²): change from baseline compared with placebo (low certainty).

1 finding from 1 review

Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
MD 0.17
1 study · 38 participants
Low

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Repaglinide · people at increased risk for developing type 2 diabetes

2 findings from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 103 participants
Low
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Repaglinide Diagnostic criteria: 1 study applied the ADA 2010 criteria (FPG ≥ 5.6 mmol/L and < 6.9 mmol/L and 2‐h glucose ≥ 7.8 mmol/L or < 11.0 mmol/L after a 75 g OGTT; Zhang 2007) · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 96 participants
Low